Abstract
Respiratory diseases account for over 5 million deaths yearly and are a huge burden to healthcare systems worldwide. Murine models have been of paramount importance to decode human lung biology in vivo, but their genetic, anatomical, physiological and immunological differences with humans significantly hamper successful translation of research into clinical practice. Thus, to clearly understand human lung physiology, development, homeostasis and mechanistic dysregulation that may lead to disease, it is essential to develop models that accurately recreate the extraordinary complexity of the human pulmonary architecture and biology. Recent advances in micro-engineering technology and tissue engineering have allowed the development of more sophisticated models intending to bridge the gap between the native lung and its replicates in vitro. Alongside advanced culture techniques, remarkable technological growth in downstream analyses has significantly increased the predictive power of human biology-based in vitro models by allowing capture and quantification of complex signals. Refined integrated multi-omics readouts could lead to an acceleration of the translational pipeline from in vitro experimental settings to drug development and clinical testing in the future. This review highlights the range and complexity of state-of-the-art lung models for different areas of the respiratory system, from nasal to large airways, small airways and alveoli, with consideration of various aspects of disease states and their potential applications, including pre-clinical drug testing. We explore how development of optimised physiologically relevant in vitro human lung models could accelerate the identification of novel therapeutics with increased potential to translate successfully from the bench to the patient's bedside.
Abstract
Rapid advancement in human ex vivo modelling is providing new opportunities for delineating novel mechanistic understandings. Combining these with evolving downstream and multi-omic analysis techniques could accelerate future therapeutic development. https://bit.ly/3b1PM0k
Footnotes
Author contributions: M.V. Humbert and T.M.A. Wilkinson conceived the project. M.V. Humbert designed and managed the review. M.V. Humbert, C.M. Spalluto, J. Bell, C. Blume, F. Conforti, E.R. Davies, L.S.N. Dean, P. Elkington, H.M. Haitchi, C. Jackson, M.G. Jones, M. Loxham, J.S. Lucas, H. Morgan, M. Polak, K.J. Staples, E.J. Swindle, L. Tezera and A. Watson wrote the review. M.V. Humbert, C.M. Spalluto, A. Watson and T.M.A. Wilkinson edited the review. T.M.A. Wilkinson supervised the project. All authors approved the final manuscript.
Conflict of interest: T.M.A. Wilkinson has received grants from the GSK group of companies, AstraZeneca, Synairgen, UK Research and Innovation, and MyMHealth, and fees or nonfinancial support from Boehringer Ingelheim, Teva, Nutricia, Chiesi and AstraZeneca, outside of the submitted work; and is an inventor on patents and is the founder and director of MyMHealth Ltd. M.V. Humbert, C.M. Spalluto, J. Bell, C. Blume, F. Conforti, E.R. Davies, L.S.N. Dean, P. Elkington, H.M. Haitchi, C. Jackson, M.G. Jones, M. Loxham, J.S. Lucas, H. Morgan, M. Polak, K.J. Staples, E.J. Swindle, L. Tezera and A. Watson declare that they have no conflicts of interest.
Support statement: The National Institute for Health and Care Research (NIHR) Southampton Biomedical Research Centre (BRC) supported this work.
- Received March 1, 2022.
- Accepted June 11, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org